NASDAQ: NEO · Diagnostics & Research
NeoGenomics (NEO) fair value: undervalued or overvalued?
As of 15 Nov 2026, Faircurve's model values NeoGenomics (NEO) at $15.88 a share. The stock last closed at $15.41, which puts the model's fair value 3.0% above the price. On the model's bands that reads as Fairly valued.
Revalued . Price is the close of 16 Nov 2026. NeoGenomics, Inc.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 15 Nov 2026 moved the fair value from $16.48 to $15.88 (-3.6%). The stock's own trading multiple fell with its price, and the fair value follows it in part: most of the move.
What the model makes of itThe price of $15.41 is 3.0% below it: Fairly valued, on a medium evidence grade.
What's nextNext report on 16 Feb 2027. Options prices imply a move of about 17% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give NEO?
The calibrated range for NEO over 63 trading days is $12.75 to $18.80. It sits around the last close, and its width comes from the volatility that NEO's own options imply (57% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $13.31 to $18.61. In 48% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 15 Nov 2026
NeoGenomics, Inc. provides cancer-focused diagnostic and testing services through laboratories across the United States, Europe and Asia.
Faircurve's model put the fair value of NeoGenomics at $15.88 a share on 15 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $16.48, so the fair value moved -3.6%. In the model's own words: "The stock's own trading multiple fell with its price, and the fair value follows it in part: most of the move." The calibrated range over 63 trading days is $12.75 to $18.80, built around the price from the volatility the stock's own options imply, and calibrated weekly against realised prices (8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The evidence grade is Medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is.
The model's overall quality score for NeoGenomics is 54 out of 100, a composite of six factors scored against comparable companies. Growth quality stands out at 77, with trailing revenue growth of 10.1% against a peer median of 3.7%. Capital discipline scores 78, with net buybacks at 1.1% of market value against a peer median of 0.0%. The balance sheet scores 18, with net debt to EBITDA at 9.60x against a peer median of 1.23x. The model compares the company with Sotera Health Company (SHC), RadNet, Inc. (RDNT), Charles River Laboratories International, Inc. (CRL), Revvity, Inc. (RVTY), Medpace Holdings, Inc. (MEDP) and Quest Diagnostics Incorporated (DGX).
Written from the figures on this page for the 15 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does NEO report earnings, and how has the stock reacted?
NeoGenomics's next earnings report is scheduled for 16 Feb 2027. Companies can move their dates.
Options prices on 16 Nov 2026 imply a move of about 13.3% in either direction through the nearest expiry, about 31 days out. That is the size the market is pricing, not a direction. NEO's 30 day implied volatility works out to about 16.6% over one month.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across NEO's last 8 reports, ignoring direction, was 8.8%.
What the options market has priced for a month's move in NEO
How does NEO score on business quality?
NeoGenomics's overall quality score is 54 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 50 | -3.8%ROIC | -9.0% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 37 | ||
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 77 | 10.1%Revenue growth, trailing | 3.7% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 78 | 1.1%Net buybacks / market value | 0.0% |
| Balance sheetNet debt to EBITDA and interest coverage. | 18 | 9.60xNet debt / EBITDA | 1.23x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 68 | 6.0 ptsEBITDA margin downside volatility, 5y | 14.8 pts |
How does NEO compare with similar companies?
The companies in diagnostics & research closest to NeoGenomics in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| VCYT Veracyte, Inc. | $24.01 | $27.86 | +16.0% | Data under review |
| SHC Sotera Health Company | $16.25 | $22.46 | +38.2% | Undervalued |
| RDNT RadNet, Inc. | $76.89 | $72.24 | -6.0% | Fairly valued |
| CRL Charles River Laboratories International, Inc. | $335.52 | $423.73 | +26.3% | Undervalued |
| RVTY Revvity, Inc. | $148.85 | $185.05 | +24.3% | Undervalued |
| MEDP Medpace Holdings, Inc. | $648.20 | $717.73 | +10.7% | Fairly valued |
| DGX Quest Diagnostics Incorporated | $262.21 | $314.32 | +19.9% | Undervalued |
| LH Labcorp Holdings Inc. | $372.46 | $465.68 | +25.0% | Low evidence grade |
What the comparable companies' multiples alone would give for NEO, the peer-implied price, is $15.21 a share on this run. The fair value weighs that against the company's own multiple.
All diagnostics & research stocks ranked by gap to fair value
NeoGenomics at a glance
NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia.
- Market value
- $2.1B
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Revenue expected, next twelve months
- $878M
- Consensus revenue growth, next fiscal year
- +11.1%
- Analysts with estimates
- 6
- Beta to the US market
- 1.01
- First valued by Faircurve
- 11 Jul 2026
At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. NEO was among them.
How the fair value is worked out: the model prices NeoGenomics on the value of the whole business, debt included, against the revenue analysts expect next year (forward EV/Sales), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for NEO was $16.48. As of 15 Nov 2026 it is $15.88, a change of -3.6%. The stock's own trading multiple fell with its price, and the fair value follows it in part: most of the move. The model revalues every stock it covers each week, and again after an earnings report.
Questions about NeoGenomics's valuation
Is NeoGenomics stock undervalued or overvalued?
On Faircurve's model, NEO reads as Fairly valued as of 15 Nov 2026. The model's fair value is $15.88 a share against a last close of $15.41, a gap of +3.0%.
What is NEO's fair value?
$15.88 a share as of 15 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $13.31 to $18.61.
What price range does the model give NEO?
$12.75 to $18.80 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.
When does NeoGenomics report earnings next?
The next report is scheduled for 16 Feb 2027. Companies can move their dates.
How much has NEO moved on past earnings reports?
Across its last 8 reports the median two session move was 8.8%, ignoring direction. The largest was -21.1% around the report of 29 Jul 2025.
How confident is the model in this valuation?
The model's evidence grade for NEO is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on NEO
The model holds no idea open on NEO today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on NEO with their outcomes. A free account is enough.